The team evaluated the effects of treatment with 5-aminosalicylic acid derivatives on renal function in patients with ulcerative colitis.
The findings of the study were published in the February issue of Alimentary Pharmacology & Therapeutics.
Some 40 patients with ulcerative colitis, in complete remission for 6 months, were randomized to either olsalazine (n = 20) or mesalazine (n = 20) for 9 months.
Of these, 36 individuals were on prior salicylate therapy.
Disease activity was the measure of clinical efficacy, and was assessed by the Harvey-Bradshaw Index.
| Mesalazine-treated patients experienced more drug related adverse events.
| Alimentary Pharmacology & Therapeutics |
Laboratory efficacy measurements included glomerular filtration rate (GFR), microalbuminuria, urinary gluthathione S-transferase (GST), and serum C-reactive protein (CRP).
Safety analysis consisted of documentation of adverse events and laboratory values.
It was found that there was no significant reduction in the GFR overall on therapy.
The levels of GFR, adjusted for baseline, were similar in the two treatment groups after 3, 6, and 9 months.
A significantly higher percentage of mesalazine-treated patients experienced drug related adverse events, all of a minor nature.
The incidence of adverse events causing early withdrawal was similar in the two treatment groups.
Dr N. Mahmud, of Trinity College and St. James's Hospital, Dublin, concluded on behalf of the group, "Treatment with mesalazine or olsalazine for 9 months had no significant impact on glomerular filtration rate."